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Introduction
Demyelinating disorders have been reported in associa-
tion with anti-tumor necrosis factor alpha (anti-TNF-
alpha) treatment in adults. Few reports exist among
children.
Objectives
We report a case of demyelination and optic neuritis in
a child treated with eternacept to increase the awareness
of the possible risk of demyelination during anti-TNF-




A 9 year old girl treated with methotrexate for 6 months
and eternacept for 3 months because of polyarticular JIA
developed loss of vision in both eyes. The weeks prior
she had been extremely tired with periods of cough and
fever. Bacterial- and Epstein-Barr-virus infection was
absent. Her well-being improved spontaneously. Mild
vitritis was diagnosed bilaterally and impaired vision was
diagnosed. MR of the brain showed periventricular
white matter lesions and lesions in hypothalamus. In
addition signs of optic neuritis were seen. Visual evoked
potential (VEP) showed delayed latency. Anti-aquaporin-
4 antibodies were not present. Cerebrospinal fluid (CSF)
examination was without pleocytosis and no infectious
agent could be demonstrated. Oligoclonal bands in the
CSF were present indicating production of gamma globu-
lin in the central nervous system.
The girl received high-dose intravenous steroid therapy
followed by oral prednisone. The treatment with etaner-
cept was stopped. Two months later her vision was
almost normal and still improving. No further neurologi-
cal symptoms have developed during prednisolone
tapering.
Conclusion
Development of cerebral demyelination might be the
first attack of multiple sclerosis and may be triggered by
anti-TNF-alpha treatment. The changes could also be
due to an inflammatory disorder caused by infection or
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